Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.77 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482041 | 0.87 | PPARD (0.77) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6474332 | 0.87 | PPARD (0.77) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6480506 | 0.87 | PPARD (1.00) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6474778 | 0.86 | PPARD (0.76) | PPARDPPARGPPARANR4A2 | |
| SCHEMBL6527568 | 0.86 | PPARD (0.75) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6474386 | 0.85 | PPARD (0.73) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6475704 | 0.84 | PPARD (0.72) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL3269096 | 0.83 | PPARD (0.56) | PPARDPPARGPPARANR4A2LMNA | |
| SCHEMBL6474624 | 0.83 | PPARD (0.65) | PPARDFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6480732 | 0.81 | PPARD (0.58) | PPARDFFAR1FFAR4PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | claimed |
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885FFAR1 22/4885FFAR4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.